Cytoki Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cytoki Pharma is a Danish biotech founded in 2019, focused on harnessing the therapeutic potential of the cytokine IL-22. The company's core technology involves engineering lipidated, long-acting IL-22 analogues, with its lead program, CK-0045, in-licensed from Novo Nordisk and now in Phase 2 development for obesity and type 2 diabetes. Cytoki is backed by prominent European life science investors and is led by a team with deep expertise in IL-22 biology and drug development. The company aims to establish IL-22 as a novel treatment paradigm that drives disease modification beyond weight loss alone.

Metabolic DiseaseObesityType 2 DiabetesInflammatory Bowel Disease

Technology Platform

Platform for engineering long-acting, lipidated analogues of the interleukin-22 (IL-22) cytokine, enabling subcutaneous delivery and extended half-life while preserving native-like function.

Opportunities

The massive and growing global markets for obesity and type 2 diabetes therapies present a primary opportunity, especially if CK-0045 can demonstrate complementary benefits to existing GLP-1 drugs.

Additionally, the novel mechanism of epithelial repair offers a first-in-class pathway into the large inflammatory bowel disease market, where current treatments do not directly address tissue healing.

Risk Factors

Key risks include clinical failure of the lead asset CK-0045 in ongoing Phase 2 trials, the high competitive intensity and commercial barriers in the metabolic disease space dominated by large pharma, and reliance on venture funding as a pre-revenue company with a single core platform.

Competitive Landscape

In obesity/type 2 diabetes, Cytoki faces competition from dominant GLP-1/GIP agonists (e.g., from Novo Nordisk, Eli Lilly) and other emerging mechanisms. Its differentiation is a non-immunomodulatory, tissue-repair-focused approach. In IBD, it would compete with anti-TNF, anti-integrin, and JAK inhibitor drugs, but its epithelial healing mechanism is novel and potentially complementary.

More companies in Biologics / Biosimilars →More companies in Denmark →